Recent News

• 04.05.2025 - Centessa Pharmaceuticals ORX750 Poster Presentation at American Academy of Neurology (AAN) Annual Meeting 2025
• 03.24.2025 - Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024
• 03.11.2025 - Leerink's Global Biopharma Conference 2025
• 03.06.2025 - Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting
• 03.04.2025 - TD Cowen 45th Annual Health Care Conference

Recent Filings

• 03.25.2025 - 144 Report of proposed sale of securities
• 03.24.2025 - 8-K Current report
• 03.24.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.24.2025 - EX-99.1 EX-99.1
• 03.24.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 03.21.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.20.2025 - 144 Report of proposed sale of securities
• 03.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.17.2025 - 144 Report of proposed sale of securities